中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 9
Sep.  2018

Efficiency of FibroTouch in evaluating liver fibrosis degree in nonalcoholic fatty liver disease patients with different levels of body mass index

DOI: 10.3969/j.issn.1001-5256.2018.09.013
Research funding:

 

  • Received Date: 2018-03-19
  • Published Date: 2018-09-20
  • Objective To investigate the efficiency of Fibro Touch noninvasive liver stiffness measurement (LSM) in evaluating liver fibrosis degree in nonalcoholic fatty liver disease (NAFLD) patients with different levels of body mass index (BMI) . Methods A total of 238 NAFLD patients who were admitted to The Affiliated Hospital of Xuzhou Medical University from June 2015 to January 2018 and underwent liver biopsy were enrolled in this study, and according to BMI, they were divided into group A (BMI < 24) , group B (24≤BMI < 28) , and group C (BMI≥28) . Fibro Touch was performed within one week after liver biopsy, and fasting blood samples were collected on the same day. The fibrosis indices were calculated. The efficiency of LSM in evaluating fibrosis degree was analyzed in all groups, and the correlation of LSM with related serological fibrosis indices was analyzed. The receiver operating characteristic (ROC) curve was plotted, and the area under the ROC curve (AUC) was used to evaluate the diagnostic value of LSM and serum markers. A one-way analysis of variance and the SNK-q test were used to investigate the differences in related indices between NAFLD patients with varying fibrosis degrees, and the Kruskal-Wallis H test was used for comparison of non-normally distributed data. The Spearman's rank correlation analysis was used to investigate the correlation between LSM and other indices. Results In group A, B, or C, there was a significant difference in LSM between the NAFLD patients with different fibrosis degrees (F = 18. 543, 22. 985, and 5. 904, P < 0. 001, P < 0. 001, and P = 0. 004) . In the NAFLD patients with progressive liver fibrosis, there was a significant difference in LSM between the patients with different levels of BMI (F = 3. 899, P = 0. 026) . LSM was correlated with Hui score, Forns index, fibrosis-4, and NAFLD fibrosis score (r = 0. 459, 0. 388, 0. 427, and 0. 422, all P < 0. 001) . LSM had the highest efficiency in the diagnosis of progressive liver fibrosis in NAFLD patients, with an AUC of 0. 870, a specificity of 86%, and a sensitivity of 70%. Conclusion Fibro Touch has good value in evaluating the liver fibrosis degree of NAFLD patients, and BMI may affect the result of LSM. LSM is well correlated with other diagnostic indices for liver fibrosis and holds promise for clinical application.

     

  • [1]LOOMBA R, SANYAL AJ.The global NAFLD epidemic[J].Nat Rev Gastroenterol Hepatol, 2013, 10 (11) :686-690.
    [2]ZHU CY, ZHOU D, FAN JG.Advances in diagnosh and treatment of nonalcoholic fatty liver disease[J].Chin J Hepatol, 2016, 24 (2) :81-84. (in Chinese) 朱婵艳, 周达, 范建高.非酒精性脂肪性肝病的诊断与治疗进展[J].中华肝脏病杂志, 2016, 24 (2) :81-84.
    [3]YOUNOSSI ZM, STEPANOVA M, NEGRO F, et al.Nonalcoholic fatty liver disease in lean individuals in the United States[J].Medicine, 2012, 91 (6) :319-327.
    [4] RINELLA ME.Nonalcoholic fatty liver disease:A systematic review[J].JAMA, 2015, 313 (22) :2263-2273.
    [5]OBARA N, UENO Y, FUKUSHIMA K, et al.Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases[J].J Gastroenterol, 2008, 43 (9) :720-728.
    [6]YANG EN, CAO WK.Research advances in noninvasive diagnosis of hepatic fibrosis[J].J Clin Hapetol, 2017, 33 (11) :2209-2213. (in Chinese) 杨二娜, 曹武奎.肝纤维化无创诊断的研究进展[J].临床肝胆病杂志, 2017, 33 (11) :2209-2213.
    [7]BOURSIER J, VERGNIOL J, GUILLET A, et al.Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by Fibro Scan in non-alcoholic fatty liver disease[J].JHepatol, 2016, 65 (3) :570-578.
    [8] CASSINOTTO C, BOURSIER J, de LDINGHEN V, et al.Liver stiffness in nonalcoholic fatty liver disease:A comparison of supersonic shear imaging, Fibro Scan, and ARFI with liver biopsy[J].Hepatology, 2016, 63 (6) :1817-1827.
    [9]Group of Fatty Liver and Alcoholic Liver Disease, Society of Hepatology, Chinese Medical Association.Guidelines for management of nonalcoholic fatty liver disease:An update and revised edition[J].Chin J Gastroenterol Hepatol, 2010, 26 (2) :120-124. (in Chinese) 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南 (2010年修订版) [J].临床肝胆病杂志, 2010, 26 (2) :120-124.
    [10]European Association for the Study of the Liver, Asociación Latinoamericana parael Estudio del Hígado.EASL-ALEH Clinical Practice Guidelines:Non-invasive tests for evaluation of liver disease severity and prognosis[J].J Hepatol, 2015, 63 (1) :237-264.
    [11]ZHENG RQ, JIN JY.Advances in the application of ultrasound shear wave elastography in liver diseases[J].Ogran Transplantation, 2017, 8 (4) :260-266. (in Chinese) 郑荣琴, 金洁.超声剪切波弹性成像在肝脏疾病中的应用进展[J].器官移植, 2017, 8 (4) :260-266.
    [12]FRAQUELLI M, RIGAMONTI C, CASAZZA G, et al.Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease[J].Gut, 2007, 56 (7) :968-973.
    [13]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatits B:A 2015 update[J].J Clin Hapetol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学会分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.
    [14]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for hepatits C:A 2015 update[J].J Clin Hapetol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学会分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.
    [15]CHALASANI N, YOUNOSSI Z, LAVINE JE, et al.The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases[J].Hepatology, 2018, 67 (1) :328-357.
    [16]HUI AY, LIEW CT, GO MY, et al.Quantitative assessment of fibrosis in liver biopsies from patients with chronic hepatitis B[J].Liver Int, 2004, 24 (6) :611-618.
    [17]BRUGUERA M, BARRERA JM, AMPURDANS S, et al.Use of complementary and alternative medicine in patients with chronic hepatitis C[J].Med Clin, 2004, 122 (9) :334-335.
    [18]STERLING RK, LISSEN E, CLUMECK N, et al.Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection[J].Hepatology, 2006, 43 (6) :1317-1325.
    [19]ANGULO P, HUI JM, MARCHESINI G, et al.The NAFLD fibrosis score:A noninvasive system that identifies hepatic fibrosis in patients with NAFLD[J].Hepatology, 2007, 45 (4) :846-854.
    [20]LEI JW, TAN BB, LI WB, et al.Value of transient elastography measured with Fibro Touch in the diagnosis of liver fibrosis in chronic hepatitis patients with hepatocellular carcinoma[J].Chin J Med Offic, 2017, 45 (9) :930-933. (in Chinese) 雷洁雯, 谭碧波, 李万斌, 等.Fibro Touch瞬时弹性成像诊断慢性乙型肝炎合并肝癌患者肝纤维化程度应用研究[J].临床军医杂志, 2017, 45 (9) :930-933.
    [21]LIM JK, FLAMM SL, SINGH S, et al.American Gastroenterological Association Institute Guideline on the role of elastography in the evaluation of hepatic fibrosis[J].Gastroenterology, 2017, 152 (6) :1536-1543.
  • Relative Articles

    [1]Jinyuan TANG, Chenfenglin YANG, Dongle LIANG, Yuhao LUO. Role of exosomes in intrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2024, 40(1): 181-186. doi: 10.12449/JCH240130
    [2]Yuanpeng MAO, Zhe YU, Aqian SONG, Hongshan WEI. From viral hepatitis to hepatocellular carcinoma: The role of exosomal microRNAs[J]. Journal of Clinical Hepatology, 2023, 39(2): 439-443. doi: 10.3969/j.issn.1001-5256.2023.02.030
    [3]Shuyang ZHANG, Yanzhen BI, Shousheng LIU, Sheng LIU, Yongning XIN. Differentially expressed microRNAs in plasma exosomes from patients with chronic hepatitis B or hepatitis B virus-related acute-on-chronic liver failure: A bioinformatics analysis[J]. Journal of Clinical Hepatology, 2023, 39(8): 1848-1856. doi: 10.3969/j.issn.1001-5256.2023.08.013
    [4]Xuemei DING, Shilun WU, Wenbing SUN. Value of preoperative microRNA-192 in peripheral blood mononuclear cells in predicting microvascular invasion of solitary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1121-1125. doi: 10.3969/j.issn.1001-5256.2021.05.028
    [5]Sheng CHEN, Guoxiang CHEN, Zhongming HE, Shujie CHENG, Jisen ZHAO. Role of miRNA in the development and progression of cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2021, 37(9): 2241-2245. doi: 10.3969/j.issn.1001-5256.2021.09.048
    [6]Xiuhong HUANG, Xiaoli XIE, Huiqing JIANG. Value of a microRNA risk score model in predicting the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1110-1115. doi: 10.3969/j.issn.1001-5256.2021.05.026
    [7]Nannan QIAN, Lulu TANG, Taohua WEI, Yue YANG, Wenjie HAO, Wenming YANG. Role and mechanism of exosome non-coding RNA in liver fibrosis[J]. Journal of Clinical Hepatology, 2021, 37(10): 2429-2434. doi: 10.3969/j.issn.1001-5256.2021.10.036
    [8]Jianheng HAO, Zhencheng LI, Ying LIU, Yiwen HOU, Yan GAO, Yuchuan MIAO, Yang LIU, Huiqin HAO. A functional analysis of differentially expressed microRNAs involved in liver injury in mice with autoimmune hepatitis induced by concanavalin A[J]. Journal of Clinical Hepatology, 2021, 37(6): 1360-1367. doi: 10.3969/j.issn.1001-5256.2021.06.028
    [9]Yan JIAO, Ying ZHANG, Honglin SHI, Wang LU, Dexi CHEN, Yu CHEN, Hongbo SHI. A bioinformatics analysis of differentially expressed proteins in plasma exosome of acute-on-chronic liver failure patients with different prognoses[J]. Journal of Clinical Hepatology, 2021, 37(4): 834-840. doi: 10.3969/j.issn.1001-5256.2021.04.022
    [10]Yao YunTing, Zhou YuanZhong, Liu Jun. Role of exosomes in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(10): 2333-2339. doi: 10.3969/j.issn.1001-5256.2020.10.038
    [11]Wu JunYi, Lai ZhiDe, Tian YiFeng, Wang YaoDong. Expression and clinical significance of serum exosomal microRNA-221-3p in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(8): 1768-1772. doi: 10.3969/j.issn.1001-5256.2020.08.018
    [12]Zhang ShiWan, Yu XueQin, Chen Fang, Mei YiHan, Mei XiaoPing. Biological characteristics of exosome microRNA and its role in the development and progression of liver fibrosis[J]. Journal of Clinical Hepatology, 2020, 36(9): 2083-2086. doi: 10.3969/j.issn.1001-5256.2020.09.039
    [13]Jia XiaoFang, Chu QiaoFang, Yuan ZhengHong. Association of exosomes with viral infection and hepatitis B virus-related liver diseases[J]. Journal of Clinical Hepatology, 2017, 33(8): 1465-1470. doi: 10.3969/j.issn.1001-5256.2017.08.010
    [14]Zhang ZhuQing, Lu ShuMing, Wang HuaLi, Xu MengYao, Li ChunYan, Xin Yue, Zhao JunJun. Expression of microRNA-222 in hepatocellular carcinoma tissue and its clinical significance[J]. Journal of Clinical Hepatology, 2017, 33(8): 1502-1505. doi: 10.3969/j.issn.1001-5256.2017.08.018
    [15]Wu JunCheng, Xu MingYi. Research advances in the association between exosomes and liver diseases[J]. Journal of Clinical Hepatology, 2017, 33(9): 1815-1819. doi: 10.3969/j.issn.1001-5256.2017.09.042
    [16]Wang QingLan, Tao YanYan, Lu: Jing, Liu Ping, Liu ChengHai. Antifibrotic mechanism of Fuzheng Huayu prescription by regulation of the differential expression of microRNAs in mouse liver[J]. Journal of Clinical Hepatology, 2016, 32(3): 503-508. doi: 10.3969/j.issn.1001-5256.2016.03.022
    [17]Lin Kun, Ci DanWangJiu, Chang ZhiHui, Liu ZhaoYu. Clinical value of circulating micro RNAs in hepatic,biliary and pancreatic carcinomas[J]. Journal of Clinical Hepatology, 2015, 31(5): 790-795. doi: 10.3969/j.issn.1001-5256.2015.05.040
    [18]Li Qiang, Zhuo QiBin, Huang YuXian, Chen Liang. Diagnosis and treatment of hepatocellular carcinoma from a new perspective of miRNAs[J]. Journal of Clinical Hepatology, 2015, 31(6): 977-981. doi: 10.3969/j.issn.1001-5256.2015.06.037
    [19]Hu XueLing, Fan GongRen. Functional role of microRNAs in viral hepatitis infections[J]. Journal of Clinical Hepatology, 2012, 28(11): 877-880.
    [20]Shi WeiMin, Shen YuYing. Investigation on influences of the changes of endotoxin in the bile on hepatic injury[J]. Journal of Clinical Hepatology, 2007, 23(2): 105-106.
  • Cited by

    Periodical cited type(9)

    1. 张芸,蔡欣奕,丁靖诺,陆圣威,陈萃英,吴婷婷,张军利,赵卫峰. 寡糖链、甲胎蛋白对乙型肝炎病毒相关肝细胞癌风险筛查与诊断价值研究. 中国全科医学. 2024(15): 1855-1860 .
    2. 杨晨,朱帆东,夏阳,楼天奇,张敏鸣,赵振华. MRI多模态影像组学鉴别肝细胞肝癌与肝富血供良性病变的应用价值. 放射学实践. 2023(05): 581-586 .
    3. 唐宇雁,谢仕斌,朱建芸. 甲胎蛋白和甲胎蛋白异质体比率(AFP-L3%)对HBV相关早期肝细胞癌的诊断效能分析. 临床肝胆病杂志. 2023(11): 2607-2613 . 本站查看
    4. 钟雪娇,郑腊梅,魏闯. 超声引导肋间神经阻滞用于腹腔镜肝部分切除术镇痛效果研究. 重庆医学. 2022(01): 45-49 .
    5. 吴鸿淞,韦朋余,李登辉,杨振宇,杜锡林. 甲胎蛋白检测肝细胞肝癌的临床应用价值. 检验医学与临床. 2021(12): 1809-1811+1824 .
    6. 叶秀娟. 血清AFP、CEA和CA125在原发性肝癌中的表达及其联合诊断价值分析. 吉林医学. 2021(09): 2234-2235 .
    7. 朱学彤,王凯瑾,周琪,许建成. 长春地区成人血清甲胎蛋白、癌胚抗原参考区间适用性验证. 临床肝胆病杂志. 2020(02): 369-371 . 本站查看
    8. 周宇辰,袁国盛,胡承光,刘俊维,任彦瑜,唐淬蓉,于乐成,杨定华. 降低AFP诊断阈值并联合检测DCP显著提高肝细胞癌的诊断率. 肝脏. 2019(05): 507-509+518 .
    9. 李政霖,侯雪晶,漆栋梁,白建荣,杨艳慧,杨丽俊,杨忠霞. 血清学指标在原发性肝癌临床诊断中的应用价值. 国际流行病学传染病学杂志. 2019(06): 495-499 .

    Other cited types(7)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (745) PDF downloads(162) Cited by(16)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return